Berkeley Bio, instead of going down with the ship at SKTO/AEGY/IEquity Corp., ought to consider other options such as breaking away and joining forces with an MJMD, or another promising mmj firm where they won't be overcome by an odor of fraud and deception from the parent company. Most acquired subsidiary contracts build in back doors, cancellations, or nonperformance clauses for exigencies like this. Though acquired, Berkeley Bio remains an independent private company. GoldNApel are tarnishing their brand if not their reputations by further consorting with that unsavory group of penny stock shysters.